FUL

H.B FullerB

NYSE / Materials

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$74.00

+29.9% vs current

Most likely

Base case

45%

Probability

Target price

$68.00

+19.4% vs current

B-

Bear case

25%

Probability

Target price

$56.00

-1.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-29

AI commentary

Primary-source earnings tone is constructive, but the T+3 setup is still mixed rather than outright bullish. The company confirmed a solid Q2 beat and higher FY2026 outlook, yet secondary post-print coverage indicated the stock sold off sharply on June 25, 2026 as investors focused on the AMS acquisition, leverage, and soft-volume concerns; the packet’s June 26, 2026 anchor close was $63.25. Headline buzz is elevated because earnings and M&A hit together, but analyst-revision breadth is still thin and social coverage is unavailable, so this remains a monitoring-style positive-leaning Hold rather than a high-conviction rerating thesis.

RankAlpha Sentiment Codex - 2026-06-29

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-23eventQ2 beat plus higher FY2026 EBITDA/EPS outlook resets the near-term baselineMedium impact

H.B. Fuller’s June 24, 2026 earnings release reported Q2 revenue up 5.8% to $950 million, adjusted EBITDA up 9% to $181 million, adjusted EPS of $1.41 up 19% year over year, record Q2 operating cash flow of $121 million, and updated FY2026 guidance to adjusted EBITDA of $650 million to $675 million and adjusted EPS of $4.60 to $4.90, with Q3 adjusted EBITDA guided to $180 million to $190 million. Management said pricing execution and restructuring savings were the main drivers, which supports a better near-term earnings floor if volume does not weaken further [#SEC-8K-2026-06-25] [#EARNINGS-TRANSCRIPT-2026Q2].

2026-11-28catalystPricing discipline, Quantum Leap savings, and cash generation remain the core self-help pathHigh impact

Primary company commentary indicates adjusted gross margin expanded 200 basis points and EBITDA margin expanded 70 basis points in Q2, driven mainly by pricing execution and restructuring savings, while net debt to adjusted EBITDA improved to 3.1x and operating cash flow reached a record second-quarter level. If those self-help levers persist through 2H26, FUL can offset a still-dynamic demand and raw-material backdrop even before any AMS benefit [#SEC-8K-2026-06-25] [#EARNINGS-TRANSCRIPT-2026Q2].

2026-12-31eventAdvanced Medical Solutions deal is the main rerating lever, but approval and leverage now dominate the debateHigh impact

The June 25, 2026 8-K says H.B. Fuller agreed on a recommended cash offer for Advanced Medical Solutions at 285 pence per share, subject to AMS shareholder approval, UK court sanction, and regulatory approvals, with expected completion by the end of calendar 2026. Management framed medical as a strategic growth market and said the deal should accelerate the shift toward a higher-growth, higher-margin mix, but the transaction also introduces financing, integration, and timing risk [#8-K-2026-06-26] [#EARNINGS-TRANSCRIPT-2026Q2].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-29 • Updated nightlySource: Internal modelMethodology